{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T07:23:51Z","timestamp":1792221831808,"version":"4.4.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2014,12,17]]},"abstract":"<jats:sec xml:lang=\"en\">\n            <jats:title>Background<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              Hospitalized medical patients are at risk for venous thromboembolism (\n              <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>\n              ). Universal application of pharmacological thromboprophylaxis has the potential to place a large number of patients at increased bleeding risk. In this study, we aimed to externally validate the International Medical Prevention Registry on Venous Thromboembolism (\n              <jats:styled-content style=\"fixed-case\">IMPROVE) VTE<\/jats:styled-content>\n              risk assessment model in a hospitalized general medical population.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Methods and Results<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              We identified medical discharges that met the\n              <jats:styled-content style=\"fixed-case\">IMPROVE<\/jats:styled-content>\n              protocol. Cases were defined as hospital\u2010acquired\n              <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>\n              and confirmed by diagnostic study within 90\u00a0days of index hospitalization; matched controls were also identified. Risk factors for\n              <jats:styled-content style=\"fixed-case\">VTE were<\/jats:styled-content>\n              based on the\n              <jats:styled-content style=\"fixed-case\">IMPROVE risk assessment model<\/jats:styled-content>\n              (aged &gt;60 years, prior\n              <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>\n              , intensive care unit or coronary care unit stay, lower limb paralysis, immobility, known thrombophilia, and cancer) and were measured and assessed. A total of 19\u00a0217 patients met the inclusion criteria. The overall\n              <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>\n              event rate was 0.7%. The\n              <jats:styled-content style=\"fixed-case\">IMPROVE risk assessment model<\/jats:styled-content>\n              identified 2 groups of the cohort by\n              <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>\n              incidence rate: The low\u2010risk group had a\n              <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>\n              event rate of 0.42 (95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              0.31 to 0.53), corresponding to a score of 0 to 2, and the at\u2010risk group had a\n              <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>\n              event rate of 1.29 (95%\n              <jats:styled-content style=\"fixed-case\">CI<\/jats:styled-content>\n              1.01 to 1.57), corresponding to a score of \u22653. Low\u2010risk status for VTE encompassed 68% of the patient cohort. The area under the receiver operating characteristic curve was 0.702, which was in line with the derivation cohort findings.\n            <\/jats:p>\n          <\/jats:sec>\n          <jats:sec xml:lang=\"en\">\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p xml:lang=\"en\">\n              The\n              <jats:styled-content style=\"fixed-case\">IMPROVE VTE<\/jats:styled-content>\n              risk assessment model validation cohort revealed good discrimination and calibration for both the overall\n              <jats:styled-content style=\"fixed-case\">VTE<\/jats:styled-content>\n              risk model and the identification of low\u2010risk and at\u2010risk medical patient groups, using a risk score of \u22653. More than two thirds of the entire cohort had a score \u22642.\n            <\/jats:p>\n          <\/jats:sec>","DOI":"10.1161\/jaha.114.001152","type":"journal-article","created":{"date-parts":[[2014,11,18]],"date-time":"2014-11-18T04:46:09Z","timestamp":1416285969000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":138,"title":["External Validation of the Risk Assessment Model of the International Medical Prevention Registry on Venous Thromboembolism (IMPROVE) for Medical Patients in a Tertiary Health System"],"prefix":"10.1161","volume":"3","author":[{"given":"David","family":"Rosenberg","sequence":"first","affiliation":[{"name":"Department of Medicine, Hofstra North Shore LIJ School of Medicine, Manhasset, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Eichorn","sequence":"additional","affiliation":[{"name":"Krasnoff Quality Management Institute, North Shore LIJ Health System, Manhasset, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio","family":"Alarcon","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hofstra North Shore LIJ School of Medicine, Manhasset, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"McCullagh","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hofstra North Shore LIJ School of Medicine, Manhasset, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"McGinn","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hofstra North Shore LIJ School of Medicine, Manhasset, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex C.","family":"Spyropoulos","sequence":"additional","affiliation":[{"name":"Department of Medicine, Hofstra North Shore LIJ School of Medicine, Manhasset, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.20983"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1177\/003693308102600205"},{"key":"e_1_3_3_4_2","first-page":"1956","article-title":"Fatal pulmonary embolism in a medical department. Clinic\u2010pathological correlations and therapeutic deliberations","volume":"143","author":"Nielsen HK","year":"1981","unstructured":"Nielsen HK, Bechgaard P, Nielsen PF, Geday E, Husted SE. [Fatal pulmonary embolism in a medical department. Clinic\u2010pathological correlations and therapeutic deliberations]. Ugeskr Laeger. 1981;143:1956\u20131960.","journal-title":"Ugeskr Laeger"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamainternmed.2014.3384"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-155-9-201111010-00011"},{"key":"e_1_3_3_7_2","unstructured":"Quality AfHRa . Chapter 2. Lay out the evidence and identify best practices: preventing hospital\u2010acquired venous thromboembolism. August 2008; 2014."},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2296"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH05-06-0385"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH04-09-0587"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-1944"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.06.004"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2010.04044.x"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/jhm.562"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.284.1.79"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.06-2993"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH13-05-0427"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.2.958"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/jth.12515"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1160\/TH14-03-0239"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11239-012-0780-0"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2007.02507.x"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1111288"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.114.001152","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T10:39:06Z","timestamp":1715596746000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.114.001152"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,12,17]]},"references-count":22,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12,17]]}},"alternative-id":["10.1161\/JAHA.114.001152"],"URL":"https:\/\/doi.org\/10.1161\/jaha.114.001152","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,17]]},"assertion":[{"value":"2014-05-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-10-22","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2014-11-17","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e001152"}}